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Simple Summary: The p53 family of proteins comprises p53, p63, and p73, which share high
structural and functional similarity. The two distinct promoters of each locus, the alternative splicing,
and the alternative translation initiation sites enable the generation of numerous isoforms with
different protein-interacting domains and distinct activities. The co-expressed p53/p73 isoforms
have significant but distinct roles in carcinogenesis. Their activity is frequently impaired in human
tumors including colorectal carcinoma due to dysregulated expression and a dominant-negative
effect accomplished by some isoforms and p53 mutants. The interactions between isoforms are
particularly important to understand the onset of tumor formation, progression, and therapeutic
response. The understanding of the p53/p73 network can contribute to the development of new
targeted therapies.
Abstract: The p53 tumor suppressor protein is crucial for cell growth control and the maintenance
of genomic stability. Later discovered, p63 and p73 share structural and functional similarity with
p53. To understand the p53 pathways more profoundly, all family members should be considered.
Each family member possesses two promoters and alternative translation initiation sites, and they
undergo alternative splicing, generating multiple isoforms. The resulting isoforms have important
roles in carcinogenesis, while their expression is dysregulated in several human tumors including
colorectal carcinoma, which makes them potential targets in cancer treatment. Their activities arise,
at least in part, from the ability to form tetramers that bind to specific DNA sequences and activate
the transcription of target genes. In this review, we summarize the current understanding of the
biological activities and regulation of the p53/p73 isoforms, highlighting their role in colorectal
tumorigenesis. The analysis of the expression patterns of the p53/p73 isoforms in human cancers
provides an important step in the improvement of cancer therapy. Furthermore, the interactions
among the p53 family members which could modulate normal functions of the canonical p53 in
tumor tissue are described. Lastly, we emphasize the importance of clinical studies to assess the
significance of combining the deregulation of different members of the p53 family to define the
outcome of the disease.
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1. Introduction
p53 has a central role in tumorigenesis; it regulates cellular response to stress signals or
oncogenic cellular stimuli by inducing transient or permanent cell-cycle arrest, DNA repair,
apoptosis, or senescence [1]. The inactivation of the p53 tumor suppressor is the single most
common genetic defect in human cancer. The mutations of TP53 have been found in nearly
all tumor types and are estimated to contribute to more than 50% of all cancers.
In the late 1990s, two novel family members TP73 [2] and TP63 [3] were described. Both
encode several proteins whose structures and functions are similar to those of p53 but not
identical, each displaying peculiar functional features revealed by mouse model studies.
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All members of the p53 family are evolutionarily conserved and have a very high
structural similarity within three main functional domains: transactivation domain (TAD),
DNA-binding domain (DBD), and oligomerization/tetramerization domain (OD/TD)
(Figures 1 and 2). All family members share significant amino-acid homology in DBD (over
60%), which enables them to bind the p53-responsive elements (p53RE) and transactivate
a large number of the same target genes. Accordingly, p63, p73, and p53 proteins form a
family of transcription factors. At the sequence level, p63 and p73 share higher homology
to each other than to p53 [4]. However, despite many overlapping roles, each member has
its unique identity and functions.
The family complexity has been enriched by the transcription from alternative pro-
moters, alternative splicing, and diverse translation initiation sites [4,5]. Consequently,
several protein isoforms with distinct N- and C- termini are encoded.
The roles of each particular p53 family member were determined by transgenic knock-
out mice. While the p53 knockout mice show high susceptibility to spontaneous and
induced carcinogenesis, thereby defining p53 as an important tumor suppressor, total p63
and p73 knockout mouse models lack a cancer phenotype. Instead, p63- and p73-null mice
exhibit various developmental deficiencies revealing their crucial functions in epithelial
and central nervous system formation, respectively [4]. Although p63 and p73 are rarely
mutated in cancer, TP63 is situated within the locus frequently amplified in squamous cell
carcinoma [6]. Their role in tumorigenesis is defined by several isoforms with opposed
functions, in the same cellular context [7]. However, their tumor suppressive potential was
not fully elucidated until the establishment of the isoform-specific knockout mice. In this
review, we summarize the structural and functional properties of different p53 and p73
isoforms and their roles in tumor formation with the emphasis on colorectal cancer (CRC).
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matching those used for the encoding exons of the TP53 gene in (A). The full-length p53α protein 
consists of two transactivation domains (TAD1 and TAD2), a proline-rich domain (PRD), a DNA-
. i i i .
i t f t lt r ative exons 9 .
ex s are s as xes f iffere t c l rs a c i se e ces i lac . I tr s 2 (i2) a 4
(i4) are shown as boxes with a striped pattern. The TP53 gene can be transcribed from two different
promoters, the canonical promoter P1 upstream of exon 1 (giving rise to the long p53/∆40p53
isoforms) and the alternative P2 located in intron 4 (giving rise to the short ∆133/∆160p53 isoforms).
The TP53 mRNAs can be alternatively spliced at intron 2 or intron 9, producing isoforms with
different N- and/or C-termini. There are four possible different start codons for mRNA translation
(ATG1, ATG40, ATG133, and ATG160) resulting in protein isoforms of varying length. (B) Modular
stru ture of the p53 protein isoforms. Fu ctional protein domains are shown in different c lors
matching those used for the enc ding exons of the TP53 gene in (A). The full-length p53α protein
consists of two transactivation domains (TAD1 and TAD2), a proline-rich domain (PRD), a DNA-
binding domain (DBD), a hinge domain (HD), an oligomerization domain (OD), and a C-terminal
domain (CTD). There are 12 distinct p53 protein isoforms differing in the composition of the structural
domains. Model adapted from [8–10].
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2. Gene Architecture and Generation of the p53/p73 Isoforms
The human TP53 gene is located on the chromosome 17p13.1 and comprises 11 exons
and two alternative exons 9β and 9γ. It has a dual gene structure due to the presence of
two functional, distinct promoters, the canonical P1 located upstream of exon 1 and the
internal P2 that lies within intron 4, from which several TP53 mRNAs can be transcribed
(Figure 1A) [11]. The TP53 mRNAs can alternatively be spliced at intron 2 or intron 9,
resulting in variants with different N- or C-termini. In addition, the TP53 mRNA can also
contain two internal ribosomal entry site (IRES) elements that mediate translation in a
cell-cycle phase-dependent manner [12,13]. Translation of the TP53 mRNA can start at
different codons, e.g., codon 1 (ATG1), codon 40 (ATG40), codon 133 (ATG133), or codon
160 (ATG160) [8,14], resulting in p53 isoforms that differ in length (Figure 1B).
Consequently, the p53 isoforms can be classified as long or short depending on the ini-
tiation of transcription and translation. Transcribed from the canonical P1, the TP53 mRNA
transcripts translate at codon 1 and/or codon 40 to encode the long isoforms (p53/∆40p53),
while transcribed from the internal P2, translation can start at codons 133 and/or 160,
giving rise to the short isoforms (∆133p53/∆160p53). The transcription from the canonical
P1 generates intron 2-spliced (also known as fully spli ed, FSp53) or intron 2-retained
(also designated as p53I2) TP53 mRNA transcripts. Translation at the codon 1 of intron
2-spliced TP53 mRNA transcript encodes the full-length p53 isoforms [8,14]. However, due
to the alternative translation initiation sites and the presence of IRES elements in the 5′
untranslated regions (5′UTR) in the TP53 mRNA, IRES-mediated translation can produce
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∆40p53 isoforms from the codon 40 [12,13,15–17]. In addition, ∆40p53 isoforms can also
be synthesized from the TP53 mRNA transcripts with retained intron 2 that are translated
only at codon 40 [8,11,14]. Initiation of transcription from the internal P2 within intron
4 generates a TP53 mRNA transcript that can be translated either at codons 133 or 160,
encoding the ∆133p53 or ∆160p53 isoforms, respectively [8,14,18]. The alternative splicing
from the exon 9 to either exons 9β or 9γ generates the TP53 mRNA transcripts that encode
β or γ isoforms, respectively. Since both exons 9β and 9γ contain premature termination
codons (PTCs), exons 10 and 11 remain untranslated in β and γ isoforms [8,11,14]. To con-
clude, depending on alternative promoter usage (P1 or P2), alternative splicing of intron 2
or intron 9, and alternative initiation of translation, different p53 isoforms can be generated.
Consequently, nine different TP53 mRNA transcripts encoded by the TP53 gene can give
rise to 12 protein isoforms, known as p53α/β/γ, ∆40p53α/β/γ, ∆133p53α/β/γ, and
∆160p53α/β/γ [8,14]. Essentially, there is an increased expression of the full-length p53 in
tumor tissue compared to corresponding normal tissue which is usually attributed to muta-
tions in p53. Depending on the p53 mutation status, the p53 isoforms can be differentially
expressed. The increased expression of different N- and/or C-terminal spliced variants has
been detected in various cancer entities, such as the ∆133p53α isoform in colon, lung, and
ovarian cancer, cholangiocarcinoma, and melanoma [9,14,19–22] or the ∆40p53α isoform in
both glioblastoma and breast cancer [14,23,24]. Furthermore, the p53β isoform is identified
and overexpressed in the head and neck squamous cell carcinoma and renal cell carcinoma,
respectively [25,26]. Interestingly, the expression profile of the N- and C-terminal spliced
variants can differ in premalignant lesion, tumor, and corresponding healthy tissue. For
example, premalignant lesions of colon adenomas are shown to express reduced levels of
N-terminal splice variant (e.g., ∆133p53α) and elevated levels of C-terminal splice variant
(e.g., p53β) compared with normal colon tissues. In contrast, the expression pattern of
these splice variants depends on the p53 status and is changed in colon carcinoma tissue
compared to colon adenoma, suggesting their role in cancer progression [19,27].
The p73 protein was discovered in 1997 as a product of the TP73 gene situated in the
region 1p36.33 that is often deleted in neuroblastoma and various other human tumors.
Frequent occurrence of loss of heterozygosity (LOH) and structural homology with the
canonical tumor suppressor p53 placed p73, together with almost concomitantly discovered
p63 protein, into the common p53 protein family [2,3]. The human TP73 gene consists of
15 exons (designated as exons 1–14, plus one alternative exon 3′) and it can be transcribed
into different mRNAs, subsequently producing several different protein isoforms (Figure 2).
Multiple mRNAs are produced as a result of the existence of two promoters combined with
the alternative splicing at the 5’- and 3′-ends. The transcription from P1 located in the 5′UTR
upstream of exon 1 gives rise to a group of transcriptionally active TAp73 isoforms. Usage
of the alternative P2 situated in the intron 3 produces N-terminally truncated isoforms that
are, thus, referred to as ∆Np73 isoforms [28–30].
The transcript generated from P1 promoter can be alternatively spliced at the 5’-end,
producing more complexity among the N-terminally truncated isoforms. In this way, three
additional isoforms are produced, namely, ∆Ex2p73 (lacking exon 2), ∆Ex2/3p73 (lacking
exons 2 and 3), and ∆N′p73 (containing alternative exon 3′) [2,29–31]. Interestingly, the
∆N′p73 transcript and the ∆Np73 transcript generated from P2 promoter produce an
identical ∆Np73 protein isoform and can be distinguished exclusively on an mRNA level.
Specifically, the ∆N′p73 transcript aberrantly contains 198 bp from the alternative exon 3′
leading to a PTC in the regular reading frame, and, as a result, the translation starts at the
same codon in exon 3′ used by the P2 transcript [30,32].
Similar to p53, an IRES element was discovered in exon 2 of the TP73 mRNA repre-
senting another possible mechanism of p73 expression regulation via CAP-independent
translation [33]. Alternative splicing is even more frequent at the 3′-end, producing seven
different transcripts named α, β, γ, δ, ε, ζ, and η [2,29,34,35]. Combining the usage of
two different promoters and splicing at 5′/3′-ends can theoretically result in 35 different
mRNAs, which can be translated into 28 different protein isoforms, but not all of them
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have been detected in cell lines or tissues so far. In general, p73 expression is often higher
in tumor tissues compared to the corresponding normal tissues. The increase in expression
is mostly attributed to the N-terminally truncated isoforms, but the TAp73 isoforms are
also found to be increased in several tumors. An increase in the variety of the C-terminally
spliced isoforms has been connected to certain tumor types. Thus, normal breast, colon,
and myeloid cells predominantly express the p73α and β isoforms, while, in breast and
colon cancer, as well as in acute myeloid leukemia, an increased level of the p73γ, δ, and ε
isoforms was observed [36–38].
3. Structure of the p53 Protein Isoforms
The canonical, full-length p53 (p53α) isoform displays a modular domain structure
and contains 393 residues that are organized in seven functional domains (Figure 1B). The
N-terminal region of the p53 protein contains two distinct acidic transactivation domains
(TAD1, residues 1–39 and TAD2, residues 40–61) that are intrinsically disordered, which
allows binding with high specificity to their interacting partners [39,40]. Each TAD can
transactivate genes independently and are required for the transactivation of different
target genes and effector pathways. Through its TAD, the p53 protein interacts with the
components of transcriptional machinery (e.g., TBP, TFIIH), proteins involved in DNA
metabolism (e.g., PCA, RPA), chromatin modifiers (e.g., p300/CBP, GCN5), and inhibitors
of p53 (e.g., MDM2, MDMX). Functional analysis based on in vivo mouse models showed
that TAD1 is important for the transactivation of the p53 target genes involved in cellular
responses to acute DNA damage, such as apoptosis and cell-cycle arrest, while both TAD1
and TAD2 can cooperate in the transactivation of genes associated with tumor suppres-
sion [41,42]. Furthermore, it has recently been shown that the induction of endoplasmic
reticulum (ER) stress-inducible genes (e.g., PTP4A1, PLK2) depends on the transactivation
activity of the TAD2 [43].
Following TA domains at the N-terminus lies a proline-rich domain (PRD, residues
62–93) that contains 15 proline residues, some as part of five PXXP motifs (where P rep-
resents proline and X any residue) important for growth suppression. These motifs have
the ability to bind SH3 (Src homology 3) domains of proteins such as c-Src and PI3K
(phosphatidylinositol 3-kinases) and mediate signal-transduction pathways [44,45]. The
PRD is shown to control modifications that influence p53 functions, e.g., activity and
stability. It contains conformationally flexible motifs that bind transcriptional coactivator
p300, involved in p53 activation through acetylation [46]. Furthermore, the PRD is impor-
tant for regulating p53-mediated apoptosis [47,48]; rs1042522 (p53 p.R72P) is a common
polymorphism in the PRD whose allele frequency differs in populations worldwide [49]
and was recently associated with the CRC risk among specific ethnic groups according to a
meta-analysis [50].
The p53 protein binds to DNA through its core domain, the conserved sequence-
specific DBD (residues 94–290). The DBD contains four conserved regions [51] and includes
the immunoglobulin-like β-sandwich that serves as a scaffold for the structural elements
involved in DNA-binding consisting of two large loops, which are held together by a zinc
atom through cysteine and histidine ligands, and a loop–sheet–helix motif [52]. It has been
recently shown that the DBD regulates conformation stability of the p53, and its absence, as
in the ∆133p53 and ∆160p53 isoforms, can destabilize the structure and trigger aggregation
propensity, ultimately causing abnormal protein function [53]. Most cancer-associated
mutations occur within the DBD, causing structural alterations (e.g., R175, Y220, G245)
or impacting DNA binding (e.g., R248 and R273) [54], which makes DBD crucial for the
tumor-suppressive functions of p53. Furthermore, p53-dependent tumor suppression and
apoptosis can be modulated by mutations in residues E180 and R181 that provide the
structural basis for cooperative binding of p53 to target promoters [55,56].
The p53 protein possesses a nuclear-localization signal (NLS, residues 305–322) that
facilitates the shuttling of p53 between the nucleus and cytoplasm. It has been shown
that the nuclear import of p53 is negatively regulated by ubiquitination of lysine residues
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319–321 within the NLS, causing the retention of p53 in the cytoplasm. Upon stress, the level
of ubiquitination reduces, and the positive charges of NLS residues are rendered unmasked
and recognized by importin α3, an adaptor molecule that facilitates nuclear import of non-
ubiquitylated p53 [57,58]. The NLS is located in the hinge domain (HD, residues 291–324),
the short linker between DBD and OD (residues 325–356). Germline mutations in the HD
(e.g., p.K305M and p.G325V) have been shown to impair apoptotic functions of mutant (mt)
p53 protein that still retains the ability to induce cell-cycle arrest [59]. Additionally, specific
missense and deletion mutations in the HD (e.g., p.R306P, p.del300-308 and p.del300-327)
cause the loss of apoptotic function and reduced ability of p53 to transactivate the BAX
promoter, but do not affect the transactivation of p21 promoter [60], which would imply
that the HD is involved in allosteric regulation of DNA binding [61].
To fulfill its function as a tetrameric transcription factor, p53 needs to exhibit its capac-
ity to form tetramers, an active form needed for binding to RE and gene transactivation,
dependent on the OD. It has been revealed that the monomer, which consists of a β-strand
and an α-helix, connects with the second monomer to form a dimer in an antiparallel man-
ner by means of their β-strands and α-helices. Two dimers connect through their α-helices
to form a tetramer. On the other hand, β-strands are not included in the interaction between
the dimers since they are located outside of the tetramer [62]. In addition, the OD contains
a leucine-rich nuclear export signal (NES, residues 340–351) that regulates subcellular
localization of p53 and is masked in the tetramers, permitting their accumulation in the
nucleus. Consequently, there seems to be a coordinated regulation of p53 tetramerization
and its nuclear retention, which is dependent on the NES placement [63]. It has been
recently shown that the positively charged residues within the NES of OD are required for
proper regulation of the p53 target genes. For example, changing lysines 351 and 357 to
glutamines does not affect localization or tetramerization status of the protein. However,
p53 is impaired in the induction of cell-cycle arrest but retains the ability to induce cell
death [64]. Many other missense mutations in the OD have been reported [65], some of
which can impair the ability of p53 to form tetramers and to activate transcription of its
target genes. It has been shown that the p53 OD mutants with the alterations in L330 (i.e.,
p.L330R, p.L330E or p.L330P) can exhibit severe homotetramerization and ubiquitination
defects and the loss of transcriptional activity. However, when co-transfected with wt p53,
they could form heterotetramers and alter the expression of p53 target genes (BAX and
p21), thereby acting as dominant-negative mutants [66].
The C-terminal domain (CTD) (residues 357–393) is an arginine- and lysine-rich ba-
sic domain that recognizes and binds nonspecifically to DNA and RNA. The CTD is
intrinsically disordered and contains NLSs, as well as the sites with the most frequent
posttranslational modifications (PTM) that include phosphorylation, acetylation, ubiquiti-
nation, methylation, neddylation, and sumoylation [39,40,67,68]. Hence, the CTD regulates
the activity of the protein. Initially, the CTD was suggested to be a negative autoregulator of
sequence-specific DNA binding. However, later studies have described positive regulatory
features of the CTD that likely depend on low-affinity electrostatic interactions between
the DNA phosphate backbone and C-terminal lysine residues [40]. It has recently been
shown that the CTD is required for the DBD to recognize p53RE, and it is able to modulate
structural changes within the DBD, thus stabilizing the association of p53 to DNA-binding
sites [40,69].
To summarize, different p53 isoforms, except the canonical full-length p53, lack part of
the N- and/or C-termini and, consequently, are deficient in some of the functional domains
(Figure 1B). The isoforms with N-terminal deletions have a designation depending on the
length of the deletion; hence, considering the lack of the first 39, 132, or 159 residues, they
are called ∆40p53, ∆133p53, or ∆160p53 isoforms, respectively. Due to the lack of the first
39 residues, TAD1 is absent in the ∆40p53 isoforms that still retain TAD2. Both TAD and
PRD are absent in the ∆133p53 and ∆160p53 isoforms that, to some extent, retain the DBD.
The ∆133p53 isoforms lack a small part of the first conserved cysteine box of the DBD,
which is completely absent in the ∆160p53 isoforms. However, the ∆160p53 isoforms do
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retain the other three cysteine boxes of the DBD. The isoforms can exhibit differences in
the C-terminus due to alternative splicing of exon 9. The α isoforms contain exons 10 and
11 that encode the OD and CTD. Due to PTCs present in exons 9β and 9γ, both β and γ
isoforms lack part of the OD and complete CTD. The first seven residues of the OD are
present in all isoforms (α, β, γ); however, the β isoforms contain an additional 10 residues,
while γ isoforms contain an additional 15 residues that differ in sequence [8,14].
4. Structure of the p73 Protein Isoforms
The full-length p73 and p53 proteins show substantial degree of homology in the com-
position of the main functional protein domains (TAD, DBD, and OD) (Figures 1B and 2B).
The level of homology between p53 and p73 proteins is the highest in their DBDs (63%),
emphasizing their central role as transcription factors binding to the promoters of various,
many overlapping, target genes. A significant level of homology exists also between their
TADs (29%) and ODs (38%) [5]. However, at the C-terminus, there is more diversity between
the family members. While p53 contains the CTD at its C-terminus, the p73 protein possesses
a unique sterile αmotif (SAM) domain, as well as an inhibitory domain (ID). Both p53 and
p73 can appear as numerous isoforms with different composition of protein domains, sus-
ceptible to different PTMs and regulatory protein interactions. This provides a broad area
for investigation in order to offer an explanation for their distinct transcriptional activity and
functions [61].
Only the TAp73 isoforms transcribed from P1 that are not subjected to additional
splicing at the 5′-end contain a complete TAD at the N-terminus, which makes them strong
transcriptional activators (Figure 2B). At first, it was considered that the p73 protein con-
tains only one unique TAD, in contrast to p53 which possesses two [70]. However, more
recent work on the interaction between the TAp73 N-terminus and different domains of
transcriptional activator p300 revealed the existence of two distinct p73 transactivation
subdomains, spanning residues 10–30 and 46–67 [71,72]. In contrast to TAp73, the ∆Np73
isoforms transcribed from P2 in intron 3 lack the first 62 residues and, consequently, do
not contain the TAD of the N-terminally intact isoforms. The presence or absence of the
TAD, defining these two groups of isoforms, is reflected in their ability to transactivate
different genes. While the TAp73 isoforms can activate the expression of various genes,
many of which are also induced by p53, the ∆Np73 isoforms are mostly transcriptionally
inactive. Moreover, the ∆Np73 isoforms act as dominant-negative inhibitors of p53 and
TAp73 [28,31]. However, inducible overexpression of the ∆Np73β isoform was found to
induce certain p53/p73 target genes such as p21, 14-3-3σ, and GADD45 causing cell-cycle
arrest, growth suppression, and apoptosis in different cell lines. This transactivation activ-
ity was dependent on the presence of 13 unique residues at the N-terminus of the ∆Np73
isoforms and the adjacent region with PXXP motifs (PRD), which together form a novel
transactivation domain specific for the ∆Np73 isoforms [73]. Similar activity was also
shown for ∆Np73γ, whereas ∆Np73αwas inactive in the growth suppression and trans-
activation [73]. In another study, overexpression of both ∆Np73β and TAp73β induced
transcription of the antiapoptotic short caspase-2S isoform, possibly contributing to pro-
survival mechanisms in tumors. The induction of caspase-2S expression was dependent on
direct TAp73β/∆Np73β binding to a specific 18 bp site in the CASP-2S promoter region.
Neither ∆Np73α nor TAp73α was able to induce caspase-2S expression under the same
experimental conditions [74]. In contrast, ∆Np73α was able to induce several genes, in-
cluding EGR1 (early growth response 1) and CDC6 (cell division cycle 6), independently of
p53 in microarray analysis [75]. In addition, ∆Np73α enhanced the expression of the TGFβ
target genes PAI-1 and Col1a1, possibly through its interaction with Smad transcription
factors and subsequent binding to Smad-binding elements (SBEs) [76]. In more recent
research, ∆Np73β and, to a lesser extent, ∆Np73αwere found to enhance the expression of
several keratinocyte genes in cooperation with ∆Np63α, having a role in skin development,
proliferation, and wound healing [77].
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The PRD of the p73 protein comprises two PXXP motifs situated between residues
84–87 and 103–106 [78]. Between the two PXXP motifs, there is Y99, a residue that was
shown to be phosphorylated by c-Abl kinase after γ-irradiation, correlating with the
induction of p73 target genes and apoptosis [79,80]. In contrast to its importance for
∆Np73β transcriptional activity, neither Y99 nor the PXXP motifs were proven to be
indispensable for the activity of TAp73β isoform in the induction of p21 expression and
apoptosis [78].
The structure of the p73 DBD is highly similar to that of the p53 protein but differs in
the L2 loop important for protein–protein interactions [81]. The DBD of the p73 protein is
responsible for its binding to REs of more than 200 different genes involved in important
cellular processes such as apoptosis, DNA repair, and neuronal and epidermal differen-
tiation. It was recently shown using a biochemical approach that even small sequence
variations in the RE could affect binding affinity and velocity of p73 with its DBD [82].
The OD of p73 comprises residues 352 to 390 and enables tetramerization of p73 and
its activity as a transcription factor. In spite of the high degree of similarity in amino-acid
sequence with the OD of the p53 protein, the heterotetramers composed of the full-length
p73 and p53 have not been identified. This was explained by the discovery of an additional
α-helix located C-terminally of the core OD (homologous to p53) whose deletion causes
a conformational instability and dissociation of the p73 homotetramer into dimers. The
absence of the second α-helix is reflected in the reduced p73 transcriptional activity [83].
As intact OD is present in all identified p73 isoforms, including both N- and C-terminally
truncated, there is a complex network of possible protein interactions to be explored.
Next to the OD, there is a long stretch of 109 amino acids connecting it to an SAM
domain which is specific for the C-terminus of p73 [83]. The SAM domain constitutes
five helices (α1 to α5) forming a globular structure, and it is considered important for
modulation of the p73 transcriptional activity [84]. It is encoded by exons 11, 12, and 13,
a region that is subjected to intensive alternative splicing. There have so far been seven
different 3′-splice variants discovered (α, β, γ, δ, ε, ζ, and η), which makes p73 the most
complex among the p53 protein family members regarding alternative splicing at the
3′-terminus [85]. The C-terminally truncated p73 isoforms are produced as a consequence
of the PTCs created by alternative splicing. Only α isoforms of p73 contain a complete
SAM domain. As a consequence of alternative splicing, the p73β isoforms lack exon 13.
Although the p73γ isoforms contain all the exons coding for the SAM domain, the usage
of the long alternative frame due to splicing at exon 11 leads to a PTC. The p73δ isoforms
lack most of the p73-specific C-terminal region (exons 11–13), resembling p53 more than
other p73 isoforms [34]. The p73ε isoforms contain parts of the p73γ and p73α reading
frames lacking exons 11 and 13. The p73ζ isoforms are produced by internal deletion
of exons 11 and 12, lacking functionally important parts of the SAM domain [35]. The
p73η isoforms are closely related to p73α but differ at exon 14. Next to the SAM domain,
at the very C-terminus, the p73α, p73ε, and p73ζ isoforms have an additional ID. The
differences in the presence and functionality of the SAM and ID have been shown to
modulate the transcriptional activity of the C-terminally spliced p73 isoforms. In that
sense, the TAp73β isoform, which lacks both the SAM domain and the ID, is a stronger
transcriptional activator than TAp73α, which contains both. Although, in TAp73α, the ID
does not directly interact with the TAD, it prevents association with the transcriptional
coactivator p300/CBP, contributing to inhibition of its transcriptional activity [86].
The differential structure of multiple p53/p73 isoforms and their potential interactions
offer a broad area for investigation of the molecular basis for their diverse biological functions.
5. Regulation of the p53 Isoforms’ Expression and Activity
The expression and function of the p53 isoforms can be regulated on the transcriptional,
posttranscriptional, translational, and posttranslational levels (Figure 3).
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that prompts alternative splicing and, thus, generates p53β isoforms. Due to IRES, the level of p53
and ∆40p53 is regulated by ITAFs (PTB, Annexin A2, PSF, DAP5, TCP80, RHA) or proteins such as
RPL26 or nucleolin. Inter stingly, ∆40p53 can be generated by the 20S rotea ome that degrades t
full-length 53 pro ein. The level of th full-length p53 protein is regulated by MDM2 t at was shown
to promote the degradation of p53β. In addition, the level of p53β is also regulated by the MDM2-
dependent neddylation, proteasome, and deneddylating enzyme Nedp1. The level of the ∆133p53α
isoform is regulated by the proteasome, as well as via autophagic degradation, upon replicative
senescence, where the proautophagic proteins (ATG5, ATG7, Beclin-1) act as positive regulators,
while the STUB1/CHIP acts as a negative regulator of ∆133p53α degradation and senescence.
As previously mentioned, the expression of p53 isoforms o the transcriptional and
posttranscriptional levels is regul ted by TP53 promoter s ge (P1 or P2) a d the alterna-
ti splicing of intron 2 or 9, which can be m dulated by different factors. The expression
of p53 i oforms is tissue-specific nd can be precisely regulated. In addition to epigenetic
events that influence the activity of TP53 promoters [11], several single-nucleotide polymor-
phisms (SNP), re specifically, their haplotypes, can modify the activity of the internal P2
promoter, thereby affecting the express on of p53 isoforms. There a eight SNPs, including
common p53 p.R72P and PIN3 Ins16bp (16 bp insertion in intron 3, rs17878362), i 11
different haplotypes ide tified within th P2. Using specific reporter gene assay constructs,
wo of the 11 haplotypes were sh wn to increase the bas line expression of ∆133p53 iso-
form [87]. In addition, a heterozygous combination of SNPs in the P2 promotor region (such
as a combination of p53 p.R72P with either SNP in intron 4, i.e., rs9895829 or rs2939430)
can affect the expression of ∆133p53, as well as the p53β isoform [88]. Furthermore, it has
been previously shown that different p53 family members and their isoforms can regulate
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the expression and function of ∆133p53 isoforms [89–92]. The transcription from P2 can
specifically be activated by the AP-1 (activator protein-1), a c-Jun/c-Fos transcription factor,
which upregulates the expression of the ∆133p53 isoform in Helicobacter pylori-infected
gastric epithelial cells [93].
On the posttranscriptional level, several factors have been shown to regulate the
alternative splicing of intron 2 or 9. The splicing factors, such as SRSF1 and SRSF3, which
are members of serine/arginine-rich (SR) proteins, have been shown to negatively regulate
the expression of p53β and p53γ isoforms [91,94]. SR proteins are essential for spliceosome
assembly and are activated by Clk (Cdc2-like kinases) [95,96]. In accordance, treatment
with Clk inhibitor TG003 and silencing of SRSF1 promote the generation of both TP53
mRNA β and γ variants and decrease the level of TP53 mRNA α variants, which would
suggest that SRSF1 regulates alternative splicing of TP53 intron 9 and favors its complete
exclusion (e.g., exons 9β and 9γ) [91]. Furthermore, downregulation of SRSF3 increased
the level of TP53 mRNA β variants and induced replicative senescence in early passages of
normal human fibroblasts, thus revealing that SRSF3 regulates alternative splicing of TP53
intron 9 and modulates the p53-mediated cellular senescence [94]. Alternative splicing and
the generation of p53β can be regulated by the DNA damage response (DDR) pathway
induced after external DNA damage (e.g., ionizing radiation (IR) and alkylating agent
MMS). IR was shown to suppress the kinase activity of the hSMG-1 protein, a member
of the PI3K family involved in the nonsense-mediated mRNA decay (NMD) pathway,
promoting the binding of RPL26 (ribosomal protein L26) to TP53 pre-mRNA. This allows
the recruitment of the splicing factor SRSF7 that prompts the alternative splicing of TP53
pre-mRNA to generate the p53β isoform, shown to be involved in the regulation of IR-
induced cellular senescence [97,98]. In addition to their role in regulating alternative
splicing, splicing factors can also regulate the transcription of p53 isoforms. Indeed, using
human aortic smooth muscle cells, it has been recently shown that SRSF1 upregulates
∆133p53α expression, but does not alter the expression of full-length p53 or the ∆40p53
isoform [99]. The ∆40p53 isoforms can be generated by alternative splicing of intron
2, which can be affected by the G-quadruplex (G4) structures located in the GC-rich
region of intron 3 in TP53 pre-mRNA [100]. The G4 structures are formed by stacking
G-quartets on top of each other, where each of G-quartet contains four guanine bases
linked via Hoogsteen hydrogen bonds stabilized by a specific cation, such as a potassium
K+ ion. The G4 structures can arise in both DNA and RNA sequences and, thus, can
affect gene transcription, mRNA splicing, and translation. Indeed, it has been shown
that G4 structures promote the splicing of intron 2, resulting in fully spliced TP53 mRNA.
In contrast, mutations that abolished G4 formation prefer retention of the intron 2 and,
consequently, increase the expression of intron 2-retained TP53 mRNA. Therefore, the
G4 structures influence the splicing of intron 2 and regulate the ratio between intron
2-spliced and intron 2-retained mRNAs [100]. In addition, the common polymorphism
PIN3 was shown to overlap with sequences included in G4 formation, and it can form a
quasi-identical G4 structure as the wt allele. PIN3 modulates the level of full-length p53
and ∆40p53 depending on the cell context and was shown to be associated with increased
cancer risk depending on the population and cancer entity [101–103]. Furthermore, the
presence of a polymorphism in intron 2 (rs1642785, PIN2) reduced the stability of p53I2
mRNA and TP53 pre-mRNA [101]. It has been recently shown that the presence of DNA
sequences prone to G4 structures adjacent to p53RE impact the transcriptional activity of
p53 family members and their α isoforms (p53/∆40p53/p73/∆Np73/p63/∆Np63); thus,
G4 could be an important transcriptional regulatory element [104,105].
On the translational level, p53 isoforms, such as full-length p53 and ∆40p53, can be reg-
ulated by IRES-mediated translation [12,17,106], which is increased under different stress
conditions that induce DNA damage (e.g., IR, etoposide, doxorubicin) [106–108], serum
starvation, ER stress [17], glucose deprivation [109], or oncogene-induced senescence [110].
IRES-mediated translation is regulated by ITAFs (IRES-interacting trans-acting factors) such
as PTB (polypyrimidine tract-binding protein), Annexin A2, PSF (PTB-associated splicing
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factor), DAP5 (death-associated protein 5), TCP80 (translational control protein 80), and
RHA (RNA helicase A) that drive translation of the full-length p53 and ∆40p53 [108,111–
114]. Interestingly, the SNPs that occur naturally in 5′UTR in TP53 can cause reduced
binding of PTB to the IRES element and weaker IRES activity [115]. Furthermore, TP53
translation is controlled by several other proteins such as RPL26 or nucleolin, which in-
teract with each other and utilize 5′ or 3′UTRs of TP53 mRNA to enhance or suppress the
p53 translation after stress, respectively [107,116]. In addition to alternative translation,
∆40p53 generation has recently been shown to also be regulated on the posttranslational
level. A novel cellular mechanism has been described and includes the activity of the
20S proteasome, whose function is not restricted to complete degradation of proteins
but instead involves cleaving some proteins at specific sites, thereby forming functional
cleavage products. Indeed, the 20S proteasome can cleave the p53 protein precisely at
position 40, generating the ∆40p53 isoform [117,118] that is capable of forming functional
heterotetramers with p53 and TAp73, consequently modulating the transcriptional activity
of p53/p73 and attenuating the expression of the p53 target genes [117,119,120]. Further-
more, under oxidative stress conditions, enhanced p53 degradation by the 20S proteasome
results in the increased level of ∆40p53 isoform [117,118].
Many different PTMs, such as phosphorylation, acetylation, ubiquitination, methy-
lation, neddylation, and sumoylation, can occur at more than 50 sites located within the
TAD, DBD, OD, and CTD of the p53 protein where the TAD and CTD are known to be
the most affected [67,68]. The CTD contains carboxy-terminal lysines that are targets for
MDM2-mediated ubiquitination. MDM2 binds p53 at the N-terminus (i.e., residues 17–23
in the TAD1 [121], promotes ubiquitin-dependent proteasomal degradation, and is critical
for maintaining the p53 level, thereby regulating the stability and transcriptional activity of
the full-length p53 protein (p53α isoform) [67,122]. However, p53 isoforms are shown to be
differentially modified by MDM2 [123]. Although MDM2 can form a protein complex with
other p53 isoforms in addition to p53α, such as p53β and p53γ, it promotes ubiquitination
and degradation of p53β only. However, MDM2-promoted degradation of p53β seems
to be independent of ubiquitination. In addition, ubiquitination and degradation of the
p53 isoforms, such as p53β/γ and ∆133p53α/β/γ, can proceed in an MDM2-independent
manner, and these processes are in part regulated by the proteasome. Furthermore, MDM2
protects p53β from degradation by the proteasome through promoting neddylation, a
process that is negatively regulated by the deneddylating enzyme Nedp1 [123]. The level
of ∆133p53α isoform can be regulated through autophagic degradation upon replicative
senescence. Both pharmacological inhibition of autophagy by bafilomycin A1 and silencing
of proautophagic proteins, such as ATG5, ATG7 and Beclin-1, have been shown to restore
∆133p53α expression. Furthermore, the level of ∆133p53α expression is regulated by
the chaperone-associated E3 ubiquitin ligase STUB1/CHIP, which was shown to protect
the ∆133p53α from autophagic degradation and, thus, acts as a negative regulator of
autophagy and replicative senescence. Interestingly, STUB1 was reported to interact with
∆133p53α and take part in its ubiquitination [124]. Although both ∆133p53 and ∆160p53
isoforms are encoded by the ∆133p53 mRNA transcript [18], recent findings have shown
that the ∆160p53 isoform can also be translated from mutated full-length TP53 mRNA;
however, the underlying mechanism still needs to be elucidated [125].
To conclude, we present some regulators and mechanisms that, on different levels, can
modulate the expression and stability of p53 isoforms, thereby influencing their biological
activities and functions.
6. Regulation of the p73 Isoforms’ Expression and Activity
The p73 expression and activity are regulated at multiple levels, including the previ-
ously described usage of multiple promoters, alternative splicing, and translation initiation
sites, involving epigenetic and PTMs, as well as interactions with other proteins (Figure 4).
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the p73 translation and protein stability. The p73 protein isoforms are also extensively regulated on
a posttranslational level. Here are shown different regulators of the TAp73 and ∆Np73 isoforms’
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NGFR, calpains, and NQO1 (through 20S proteasome). On the contrary, antizyme (Az) pathway and
ligase PIR2 specifically target the ∆Np73 isoforms for degradation after DNA damage.
The p73 expression is intensively regulated transcriptionally in response to differ-
ent stimuli such as DNA damage, viral oncogenes, proliferative signals, and epigenetic
modifications [126–131]. The main transcriptional factor inducing the expression of the
TP73 gene is E2F-1, which affects only P1-driven transcription. This regulation is crucial
for the induction of apoptosis in the absence of functional p53 and is not dependent on
posttranscriptional regulation by p14ARF and MDM2 [132,133]. Histone acetyltransferase
PCAF (P300/CBP-associated factor) stabilizes E2F-1 by acetylation, leading to an increase
in TAp73 expression [127]. The same group later discovered that the regulation of p73
expression by E2F-1 could be modulated by NAD+-dependent histone deacetylase hSirT1
through its interaction with PCAF. The interaction of hSirT1 and PCAF represses TAp73 ex-
pression as they are co-recruited with E2F-1 on the P1 promoter [134]. The E2F-1-mediated
p73 transactivation is also inhibited by the transcriptional repressors C-EBPα and ZEB,
bot affecting P1 [130,135]. More precisely, 1 kb regulatory fragme t was identified
ithin intron 1 of the TP73 gene just upstream of the initiating codon ATG in ex n 2, which
contains six consensus ZEB-binding sites [130]. Later discovered, a polymorphic deletion
of 73 bp in this region was detected in normal and tumor tissue, with a higher frequency in
patients with breast and colorectal cancer compared to healthy controls. The presence of
the allelic variant correlated with higher TP73 expression in the tumors [136]. Moreover,
the same group later reported association of the absence of the 73 bp fragment with adverse
clinicopathological parameters in a cohort of colorectal cancer patients [137]. In addition
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to E2F-1, the EGR1 transcription factor, which is quickly induced as a response to various
environmental conditions, also activated the transcription of the TAp73 isoforms [138].
More recently, Nrf-2 (nuclear factor erythroid 2-related factor 2) was discovered to bind
both P1 and P2 inducing the transcription of TAp73 and ∆Np73 isoforms. Both Nrf-2
putative binding sites contain CpG methylation islands; however, they showed opposite
behavior toward demethylation in breast cancer [139]. GemC1 (geminin coiled-coil domain-
containing protein 1) was recently recognized as the transcriptional activator of TAp73
in different multiciliated epithelia. GemC1 interacts with both the E2F-5 transcription
factor and the p73 protein, forming a trimeric complex important for the induction of TP73
promoter activity [140].
Although the p73 transcripts are subjected to intensive 5′- and 3′-terminal splicing,
the mechanisms governing the generation of particular splice variants are still poorly
understood. It was found that the expression of ∆Ex2p73 isoform is induced by activation
of EGFR (epidermal growth factor receptor) by its ligand amphiregulin in human hepa-
tocellular carcinoma cells and normal hepatocytes. Generation of the ∆Ex2p73 isoform is
dependent on the activation of JNK1 (c-Jun N-terminal kinase 1) and the downregulation of
the mRNA splicing factor SLU7 [141]. Regarding the regulation of p73 mRNA stability, the
RNA-binding protein RNPC1 recognizes and binds to the CU-rich element in the 3′UTR of
p73, contributing to the stability of p73 mRNA and increasing its expression. RNPC1 itself
is a target of p53 and p73, thus forming a novel feedforward loop [142]. Recently, it was
discovered that the ribosomal protein RPL26, which was previously shown to regulate p53
translation, can control p73 mRNA translation and protein stability [143].
The p73 protein is subjected to numerous PTMs (mainly phosphorylations and acetyla-
tions) throughout its functional domains, which modulate its activity and stability [144–146].
Steady-state levels of the p73 protein are kept low under normal physiological conditions by
different mechanisms mainly involving the ubiquitin-proteasome system. Several ubiquitin
E3 ligases have been implicated in the regulation of p73 protein stability and degradation [147].
Although MDM2 ligase, the main regulator of the p53 protein turnover, was found to bind
and inactivate the p73 protein, it does not cause its proteasomal degradation [148–151]. The
first ligase identified causing the p73 protein degradation was Hect ubiquitin-protein lig-
ase Itch which binds and ubiquitinates both TAp73 and ∆Np73 isoforms, mediating their
proteasomal degradation [152]. In contrast, N4BP1 (Nedd4-binding partner-1) and Yap1
(Yes-associated protein 1) abrogate p73 degradation by Itch through their interaction with
Itch and p73 itself, respectively [153,154]. Another member of the Itch family, Nedd4 ligase,
was found to bind both TAp73 and ∆Np73 isoforms, but was unable to cause their degrada-
tion due to its inability to catalyze their ubiquitination. On the other hand, another ligase,
NEDL2, was able to bind and ubiquitinate both isoforms; however, instead of degradation, it
caused their stabilization [152]. Itch protein level is decreased after DNA damage, causing
the stabilization of TAp73 but not ∆Np73. As ∆Np73 was degraded after DNA damage
independently of Itch, it implicated another mechanism of its regulation. Later discovered,
the ring finger ubiquitin ligase PIR2 was able to differentially control the TAp73 and ∆Np73
protein stability [155]. While the PIR2 expression itself is strongly induced by TAp73, PIR2
causes selective degradation of ∆Np73 after DNA damage, increasing the TAp73/∆Np73
ratio, which is indicative of apoptosis induction and chemosensitivity of tumor cells in general.
PIR2 forms a strong interaction with ∆Np73, inducing its ubiquitination and subsequent
proteasomal degradation [155]. Another mechanism of selective ∆Np73 degradation after
DNA damage is c-Jun-dependent and mediated by the antizyme pathway [156]. The newest
findings reveal the complex regulation of the p73 function and degradation by the interplay
of two different E3 ligases, namely, Pirh2 and AIP4. Pirh2 is recognized as a key regulator
of AIP4 that was previously found to inhibit p73 function by promoting its ubiquitination
and degradation [157]. The level of p73α isoforms that contain the SAM domain can be regu-
lated by NQO1 (NAD(P)H quinone oxidoreductase 1) through a ubiquitination-independent
mechanism mediated by 20S proteasome. This pathway is also involved in p53 regulation.
NQO1 physically interacts with p73α, p53, and the 20S proteasome, impeding p53/p73α
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20S proteasomal degradation [158]. In addition to the proteasome-mediated degradation,
the levels of different p73 isoforms can be regulated by calpains which are found to cleave
p73 at two possible sites (located in the TAD and OD) [159]. The calpain-dependent regu-
lation of p73 protein level is implicated in the chemosensitivity of ovarian cancer cells after
cisplatin treatment through modulation of apoptosis [160]. Recently, a novel mechanism of
p73 degradation was discovered through the NGFR (nerve growth factor receptor)-facilitated
chaperone-mediated autophagy. NGFR directly binds the DBD of p73 and suppresses its
transcriptional activity [161].
Numerous regulators and mechanisms of the p73 isoforms’ expression and stability
have been discovered to have an impact on their activity and biological functions. Of
particular interest are the mechanisms involved in differential isoform regulation, especially
those affecting the TAp73/∆Np73 ratio, which could be used as a potential biomarker and
basis for targeted therapy.
7. Biological Activity and Functions of the p53 Isoforms
p53 is a transcription factor, which, via multiple mechanisms, regulates the transcrip-
tion of a plethora of target genes whose products exert various biological functions [162,163].
The diverse biological activities and functions of p53 can be explained in part by the ex-
pression of p53 isoforms and their potential interactions in a tissue-specific manner [11].
Based on the results of numerous studies, including clinical studies, in vivo models, and
in vitro cellular models, it seems that the cellular response of p53 corresponds to the co-
expression of p53 isoforms and their interactions, thus influencing different pathways.
Consequently, the unbalanced expression of p53 isoforms can cause cancer, premature
aging, inflammation, developmental disorders, or deficiency in tissue regeneration [8,14].
To investigate biological activities of p53 isoforms, several small interfering RNAs
have been designed that specifically target a subgroup of p53 splice variants. Furthermore,
different antibodies that recognize the epitopes within different functional domains of p53
have been developed which can detect specific subgroups of p53 protein isoforms [8].
Due to the highly conserved structure of p53 through evolution, different in vivo models
(zebrafish, Drosophila, mouse) have been developed to investigate the biological activities
of p53 isoforms and their involvement in different cellular processes that are associated
with tumorigenesis [10,14,164,165]. To date, many biological functions involving p53 iso-
forms have been described and, depending on the cell/tissue and origin/type (e.g., malig-
nant/nonmalignant, human/mouse/zebrafish, skin/colon/lung/prostate/breast/brain, etc.),
they include cell-cycle regulation [11,19,90,99,120,166–170], apoptosis [11,91,120,170–176],
senescence [19,27,165–167,177,178], DNA repair [167,176,178–180], pluripotent and embryonic
stem-cell regulation and cancer stemness [171,181–183], normal and cancer cell
metabolism [109,184,185], autophagy [186], proliferation [99,175,187–190], cellular invasion, mi-
gration, and angiogenesis [188,190–192], immunosuppression [193,194], and inflammation [189].
It has been shown that p53 isoforms can regulate cell fate outcome in response to
stress signals by differentially modulating target gene expression in a p53-dependent and
p53-independent manner. For example, the zebrafish TP53 gene (Zp53), in addition to
Zp53α, encodes Zp53β, Z∆Np53α, and Z∆113p53α, homologous to human p53β, ∆40p53α,
and ∆133p53α, respectively. In response to stress signals, Z∆113p53α is transactivated by
the full-length Zp53 and interferes with Zp53 functions by modulating the expression of
p53 target genes, thereby antagonizing apoptotic activity via induction of antiapoptotic
bcl2L expression and by interacting with p53 [173,174]. Comparable activity is observed
in human cells, where ∆133p53 was shown to act as a negative modulator of p53 activity.
It has been shown that p53-mediated apoptosis is reduced in cells co-transfected with
∆133p53 and p53 [11]. In addition, upon low doses of doxorubicin, full-length p53 induces
∆133p53 expression which antagonizes p53-dependent apoptosis and G1 cell-cycle arrest,
without altering p53-dependent G2 cell-cycle arrest. These effects could be explained by
the ability of ∆133p53α to directly interact with p53α and to differentially modulate the
expression of p53 target genes p21, MDM2, and Bcl-2 [90]. In addition, when overexpressed,
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∆133p53 displaces p53α from promoters of p53-inducible genes, such as p21, miR-34a, BAX,
and PUMA [181]. Interestingly, Z∆113p53/∆133p53 were shown to bind novel p53RE in the
promoters of DNA repair genes (e.g., rad51/RAD51, lig4/LIG4, and rad52/RAD52) [179,180].
Comparable to ∆133p53, ∆40p53 was also shown to act in a dominant-negative manner
toward p53α and, when co-transfected with p53, can impair p53-mediated transcriptional
activity, apoptosis, and growth suppression [16,195,196]. Furthermore, in response to ER
stress, ∆40p53 and p53α were shown to have different effects on the cell cycle. While
p53α induces G1 cell-cycle arrest, ∆40p53 was shown to induce G2 cell-cycle arrest via
upregulation of 14-3-3σ [197]. However, high expression of ∆40p53 in ∆40p53-lentivirus-
infected melanoma cells was shown to activate endogenous p53 and form ∆40p53/p53
heterotetramers that alter promoter occupancy of apoptotic gene PIDD and cell-cycle arrest
gene p21, thereby promoting apoptosis over cell-cycle arrest upon γ-irradiation [172]. The
p53β isoform was shown to differentially bind to promoters, and it can enhance expression
of p53 target genes in a promoter-dependent manner. For example, while endogenous
p53α preferentially binds to p21 or MDM2 promoters rather than the BAX promoter,
endogenous p53β preferentially binds to BAX or p21 promoters rather than the MDM2
promoter. In addition, when co-expressed with p53, p53β enhances p53 transcription
activity on BAX, but not p21. Contrary to ∆133p53α and ∆40p53, p53β enhances p53-
mediated apoptosis [11].
Increasing evidence implicates ∆133p53α and p53β as regulators of cellular senes-
cence [19,27,165–167,177,178]. The characteristics of cellular senescence include elevated
expression of cell-cycle arrest markers (p21, miR-34a, p16INK4a), increased senescence-
associated β-galactosidase activity, and a senescence-associated secretory phenotype
(SASP) that includes secretion of proinflammatory SASP cytokines such as IL-6 and IL-
1β. Several studies have reported the specific senescent-associated signature of p53 iso-
form expression that is characterized by reduced expression of ∆133p53 and elevated
expression of p53β [19,166,167,177,178]. The senescent-associated signature of p53 isoform
expression was observed in different human cells that underwent senescence, such as nor-
mal human fibroblasts, T-lymphocytes, astrocytes, and primary fibroblasts derived from
Hutchinson–Gilford progeria syndrome (HGPS) patients [19,166,167,177,178]. Interestingly,
cellular senescence can be induced by ∆133p53 knockdown and/or overexpression of
p53β [19,166,177]. However, the reconstituted expression of ∆133p53 was shown to extend
replicative lifespan and to delay senescence [166,167,177,178]. Interestingly, diseases (colon
adenoma and neurodegenerative diseases, such as Alzheimer’s disease and amyotrophic
lateral sclerosis) with senescence features were also shown to have a senescent-associated
signature of p53 isoform expression [19,177].
Upon DNA damage, full-length p53 regulates the expression of its target genes in-
volved in cell-cycle arrest, DNA damage repair, apoptosis, or senescence to maintain
genome stability. However, p53α promotes only some DDR pathways, such as excision re-
pair pathways (BER, MMR, NER), while inhibiting double-strand break (DSB) repair mech-
anisms, such as homologous recombination (HR), nonhomologous end joining (NHEJ),
and single-strand annealing (SSA) [198–203]. Furthermore, p53 was shown to repress
RAD51 expression and inhibit RAD51 foci formation in response to DNA damage [204]. In
addition, p53 represses E2F-1 [205], a positive regulator of RAD51 expression under DNA
damage conditions [206]. Interestingly, both Z∆113p53 and ∆133p53 are strongly induced
upon DNA damage and are shown to promote DSB repair via upregulating the expression
of key DSB repair genes, such as rad51/RAD51 (needed for HR), lig4/LIG4 (needed for
NHEJ) and rad52/RAD52 (needed for SSA) [179]. Although such transcriptional regulation
seems to proceed independently of full-length p53, the ∆133p53-mediated DSB repair is
coordinated with p73 [180]. It has been shown that ∆133p53 can form a complex with
TAp73 [119,180] and, when co-expressed ∆133p53 and p73, can act synergistically to pro-
mote the expression of key DSB repair genes, thereby significantly promoting all three DSB
repair mechanisms [180]. Furthermore, depending on the cell context, ∆133p53 was shown
to facilitate DSB repair by increasing the level of RAD51, a component of HR, via upregula-
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tion of E2F-1 in HGPS fibroblasts [167] or by enhancing the repair of 53BP1-positive foci, a
component of NHEJ, in irradiated astrocytes [178].
The p53 isoforms are also involved in induced pluripotent stem cell (iPSC) and em-
bryonic stem cell (ESC) regulation. It has been previously reported that overexpression of
p44 (homologous to human ∆40p53) impairs the regenerative capacity of adult stem cells
while enhancing the regenerative capacity of ESC in mouse models [171,183]. Specifically,
∆40p53 was shown to regulate the level of the IGF-1 receptor, thereby controlling the switch
from pluripotent ESCs to differentiated somatic cells by regulating IGF signaling [171].
Interestingly, human iPSCs and ESCs show elevated levels of ∆133p53 compared to p53α
and reduced levels of p53-inducible senescence-mediating genes (e.g., p21, miR-34a, PAI-
1, IGFBP7) [181]. In line with this, the overexpression of ∆133p53 in human fibroblasts
repressed the expression of p53-inducible senescence-mediating genes and enhanced repro-
gramming efficiency to iPSCs that are characterized by lower rates of somatic mutations
and reduced chromosomal aberrations compared to iPSCs derived from p53 knockdown
fibroblasts [176,181]. Since the tumorigenicity of iPSC represents a serious safety concern,
iPSCs derived from overexpressed ∆133p53 have better genetic quality [176,181] and could
have a strong potential in regenerative medicine.
Recent research has shown that the p53 family of proteins is involved in the trans-
activation of metabolic enzymes included in glucose, nucleotide, amino-acid, and lipid
metabolism, as well as mitochondrial metabolism and autophagy [207–209]. Consequently,
in human tumors, particularly CRC, the loss of tumor suppressor activity of p53 and
changes in signaling pathways associated with oncogenes MYC, HIF, and KRAS, as well
as PI3K/AKT/mTOR axis, are known to play a role in deregulated cellular energetics, an
established hallmark of cancer [210–212]. Interestingly, evidence points to the involvement
of particular p53 isoforms in normal and cancer cell metabolism. For example, it was shown
that ∆133p53 binds and utilizes the TAD of ∆Np63 to upregulate the expression of GLUT1
and 4 (glucose transporters), as well as the expression of PGM1 (phosphoglucomutase-1),
which drives glycolysis in tumor cells [184]. It has been shown that the oxidized form of vi-
tamin C is structurally similar to glucose and is efficiently taken up via GLUT1 transporters
by highly glycolytic cancer cells, such as BRAF or KRAS mutant CRC cells. Once inside
the cell, vitamin C elevates reactive oxygen species (ROS) levels that inactivate glycolytic
enzyme GAPDH (glyceraldehyde 3-phosphate dehydrogenase), ultimately leading to an
“energy crisis” and cancer cell death [213,214]. Accordingly, due to overexpressed GLUT1
transporters, tumors overexpressing both ∆133p53 and ∆Np63 show increased uptake and
higher sensitivity to vitamin C, a feature potentially exploitable for cancer treatment [184].
The ∆40p53 isoforms have also been shown to be implicated in glucose homeostasis of
normal and cancer cells. Indeed, loss of ∆40p53 reduced β-cell proliferation and impaired
glucose homeostasis in mice leading to diabetes and premature death [185].
Many biological activities of the p53 isoforms have been described in the context of
cancer biology. Here, we present only some of the studies that investigated such cellular
processes. One is angiogenesis that is inhibited by full-length p53. Bernard and coworkers
investigated the role of ∆133p53 in tumor angiogenesis and tumor progression using
human glioblastoma cell line U87. The results showed that ∆133p53α and ∆133p53γ
but not ∆133p53β promote angiogenesis, while the ratio between p53 and ∆133p53α
is important for its regulation. Furthermore, depletion of ∆133p53 isoforms inhibited
angiogenesis and glioblastoma tumor growth in in vivo models (chicken chorioallantoic
membrane and mice xenografts) [190]. The role of ∆133p53 in promoting invasion and
metastasis was confirmed using a mouse model. The ∆122p53 (homologous to human
∆133p53)-expressing cells increased the migratory phenotype that was shown to depend
on SASP factors (proinflammatory cytokine IL-6 and chemokine CCL2). Furthermore,
∆122p53 promoted lung metastasis in a B16 mouse melanoma metastatic model [191].
Recent findings correlated ∆133p53β expression with an immunosuppressive environment
and chemoresistance. For example, prostate cancers with increased ∆133p53β were shown
to exhibit an immunosuppressive phenotype (e.g., increased PD-1, PD-L1, CSF1R cells)
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and immune cell infiltration (such as T cells and CD163+ macrophages). Interestingly,
∆133p53β was shown to directly regulate the mRNA expression of CD274 that encodes
the PD-L1 immune checkpoint marker. Furthermore, prostate cancers with a high level of
∆133p53βmRNA were associated with poor patient outcome [194]. Elevated ∆133p53β
was shown previously to be associated with immunosuppressive and chemotherapy-
resistant features of glioblastoma [193]. Both chemoresistance and increased metastatic
potential can result due to the presence of cancer stem cells (CSC). Recently, ∆133p53β was
shown to enhance the cancer cell stemness potential of breast cancer cells and to regulate the
expression of SOX2, OCT3/4, and NANOG, key cell pluripotency/reprogramming genes,
resulting in increased mammosphere-forming ability and metastatic potential of cancer
cells. Furthermore, etoposide treatment of breast cancer cells increased CSC formation
and elevated the level of ∆133p53β, as well as SOX2, OCT3/4, and NANOG, which can
increase the risk of resistance and cancer recurrence [182]. In addition, ∆133p53 expression
was shown to be associated with 5-fluorouracil chemoresistance of cholangiocarcinoma
cells [215]. Both ∆133p53 and ∆160p53 isoforms have a truncated DBD that influences the
conformation stability of these short isoforms compared to their full-length counterparts
and, thus, can alter their function [53]. Most cancer-associated mutations lie within the
DBD domain of p53 and can cause a “gain-of-function” (GOF) phenotype characterized by
enhanced cell survival, proliferation, invasion, and migration. It has been recently shown
that the DBD mutants (e.g., such as p.R175H, p.G245S, p.R248Q, p.R273H, and p.R280K)
with oncogenic GOF functions have an overexpressed ∆160p53 isoform. Furthermore,
the ∆160p53 isoform was shown to be required for the survival of the DBD mutants
after etoposide treatment, and it is responsible for the GOF features (e.g., inhibition of
apoptosis, promotion of proliferation, and enhanced adhesion and invasion) observed in
DBD mutants. Accordingly, knockdown of the endogenous ∆160p53 isoform was shown
to inhibit GOF and to restore apoptosis of DBD mutant cells (i.e., A431 and HT29 cells that
express p53 p.R273H) after treatment with thapsigargin, an ER stress-inducing agent [125].
Here, we presented some of the p53 isoforms and their biological activities associated
with carcinogenesis and age-related diseases; however, their biological functions in cancer,
especially CRC are described later in more detail.
8. Biological Activity and Functions of the p73 Isoforms
The p73 protein exerts its functions mainly by acting as a transcription factor affect-
ing the expression of numerous target genes related to tumor suppression, as well as
to various non-oncogenic cellular processes [216]. Multiple roles of the p73 protein in
crucial processes involved in neurogenesis, sensory pathways, and homeostatic control
have been revealed by the global p73-knockout (Trp73−/−) mice that exhibit severe neu-
rological, pheromonal, reproductive, and inflammatory abnormalities [217]. These mice
were created by deletion of exons 5 and 6 of the Trp73 gene encoding the DBD and were,
thus, deficient for the expression of all p73 isoforms. As a consequence, it was impossible
to attribute specific biological functions observed to the activity of a particular isoform.
Moreover, the initial experiments on Trp73−/−-mice failed to show increased susceptibility
to spontaneous tumorigenesis, most probably due to their short lifespan [2]. Since its
discovery and recognition as a member of the pivotal tumor suppressor p53 family, the p73
protein was presumed to be itself involved in tumorigenesis. However, the extremely low
frequency of the TP73 gene mutations in cancer and initial experiments on Trp73−/−-mice
failed to support its potential tumor suppressor role [2]. Later developed heterozygous
Trp73+/− mutant mice showed increased incidence of diverse spontaneous tumors often
manifesting LOH. Moreover, mice heterozygous for both p53 and p73 mutation exhibited
an even more aggressive tumor phenotype than the Trp53+/− mice bearing only mutation
of p53 [218]. These results supported the involvement of p73 in tumor suppression and
suggested complex interrelations between the p53 family members. In order to specify
the contribution of specific p73 isoforms to the observed phenotypes, several knockout
mouse models for particular group of isoforms were consequently developed [219]. The
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roles of p73 in tumorigenesis and other biological functions were especially complicated
to determine due to the existence of TAp73 and ∆Np73, two principal groups of isoforms
which generally show distinct functions. TAp73-knockout (TAp73−/−) mice lacking exons
2 and 3 that encode the TAD showed increased incidence of spontaneous tumors (espe-
cially lung adenocarcinoma) and genomic instability (aneuploidy) [220]. At the same time,
another group also reported the role of TAp73 in the maintenance of genomic stability as
TAp73-knockout MEFs showed increased polyploidy and aneuploidy in the absence of
p53 [221].
Maintenance of genomic stability is crucial in cancer prevention, especially upon DNA
damage. In parallel with work on knockout models, numerous expression studies on
cell models supported the role of p73 isoforms in molecular processes related to tumor
suppression such as cell-cycle regulation, DNA repair, apoptosis, and senescence [221–223].
The TAp73 isoforms as transcriptional factors are involved in the regulation of
the G1/S and G2/M cell-cycle checkpoints, acting as repressors of a plethora of genes
(CDC25B, CDC25C, CDC2, CCNB1, CCNB2, and TOP2A) and as inducers of p21, p57, and
GADD45 [224–226]. In addition, the p73 isoforms (TAp73α and ∆Np73α) are important
for cell-cycle progression even under normal physiological conditions, as they accumulate
during G1/S cell-cycle transition with a peak in the S phase. In cycling cells, both p73
isoforms bind p53RE in the promoters of cell-cycle genes, competing with p53 and imped-
ing its repressing function. Downregulation of p73 with specific siRNAs led to a decrease
in the expression of genes involved in G1/S and G2/M progression and a reduction in
cell proliferation [227]. TAp73 binds to the promoters and activates the transcription of
several genes involved in HR DNA repair, namely, Rad51, BRCA2, Mre11, and Rad50 [228].
In addition, p73 was found to be induced during DDR caused by bile acids/salts activating
genes participating in the BER, such as glycosylases SMUG1 and MUTYH [229].
In the case of excess DNA damage, when the cellular mechanisms are not able to
repair the damage, cells are driven to cell death (apoptosis) or permanent cell-cycle exit
(senescence). Very early after its discovery, p73 was recognized as an inducer of DNA
damage-induced apoptosis, mainly via the transcriptional activation of the components
of the extrinsic (CD95, DR4, DR5) and intrinsic (BAX, NOXA, PUMA, BID, p53AIP1,
GRAMD4) apoptotic pathways [230,231]. In addition, TAp73 is involved in the induction of
apoptosis independently of transcriptional activation through its cleavage by caspase-3 and
-8 and subsequent localization to mitochondria [232]. Recently, a transcription-independent
role of p73 in the mitochondrial pathway was further supported by the interaction of
TAp73 with antiapoptotic factor Bcl-XL, which increases apoptosis [233].
The functions of ∆Np73 isoforms are mostly exerted through their dominant-negative
effect on TAp73 and wt p53, impeding their activity on numerous target genes. In contrast
to TAp73−/−-mice, ∆Np73-knockout mice expectedly were not prone to tumor formation
in agreement with its potentially oncogenic function [234]. ∆Np73 isoforms are found
to be upregulated in different cancer types, which often correlates with increased resis-
tance to therapy, aggressiveness, and worse disease outcome. In addition to inactivating
p53, ∆Np73 is able to inhibit another important tumor suppressor, Rb, causing its hy-
perphosphorylation [235]. It was shown that ∆Np73 contributes to cell immortalization
by cooperating with oncogene Ras in the process of cell transformation [236]. There are
several discoveries that support ∆Np73 contribution to chemoresistance of tumor cells. For
example, ∆Np73α induces expression of the MDR1 gene, also known as ABCB1, and its
product p-glycoprotein (p-gp) by inhibiting p53 function [237,238]. In addition, ∆Np73
induces the expression of ABCB5 that, as p-gp, is responsible for multidrug resistance [238].
∆Np73β interacts with the DNA damage sensor protein 53BP1, inhibiting transmission
of the DNA damage signal downstream in the DDR cascade, thereby providing another
possible mechanism contributing to the tumor’s resistance to therapy [234].
During the last decade, an important role of p73 in the regulation of angiogenesis
emerged [239]. While oncogenic ∆Np73 was expectedly found to promote angiogenesis,
TAp73 was attributed with both positive and negative regulatory roles [240–243]. Inhibition
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of angiogenesis by TAp73 is in agreement with its general tumor suppressor role and is
achieved through the MDM2-mediated degradation of the principal angiogenic regulator
HIF1-α (hypoxia-inducible factor 1α) [243]. On the other hand, the positive effect of TAp73
on vessel formation could be connected to its increased expression found in several tumors,
as well as its role in cell survival, contradicting its typical tumor suppressor role [36,244].
Stabilization of TAp73 in the condition of hypoxia leads to activation of proangiogenic
genes, including Vegf-A [241].
p73 is extensively implicated in normal and tumor cell metabolism, contributing to
adaptation to stress conditions, mainly by regulating the expression of different target
genes. TAp73 directly transactivates mitochondrial Cox4il (complex IV subunit cytochrome
C oxidase subunit 4 isoform 1) involved in mitochondrial metabolism, preventing ROS
accumulation and premature aging in mice [245]. Interestingly, TAp73 also contributes
to redox homeostasis by facilitating the translation of specific mitochondrial transcripts,
affecting the translational machinery itself [246]. High-throughput studies of cancer cell
models ectopically expressing TAp73α or TAp73β have confirmed the influence of the
TAp73 isoforms on numerous metabolic pathways, both catabolic and anabolic, with
seemingly opposite effects [247–250]. These results confirm that p73 is a multifaceted
protein, as some of its metabolic roles, e.g., in glycolysis and anabolic pathways, may be
easily interpreted as tumorigenic, contradicting its established tumor suppressor role. On
the other hand, Agostini and coauthors suggested that the metabolic changes induced by
ectopic expression of the TAp73β isoform may serve as a response to prevent accelerated
senescence and aging, and not to promote cellular proliferation [247]. However, further
investigations are needed to clarify the meaning of the various metabolic changes caused
by the ectopic expression of both TAp73α and TAp73β. TAp73 is also involved in the
metabolism of amino acid glutamate, as it regulates the expression of GLS2 (glutaminase
2) that converts glutamine into glutamate [251,252]. Consequently, the loss of TAp73
affects in vivo GABA and glutamate levels in cortical neurons [251], and its presence
in medulloblastoma cells leads to a glutamine addiction phenotype, where the lack of
glutamine inhibits cell proliferation [252].
The ∆Np73 isoforms have also been implicated in glucose metabolism. Deletion
of the ∆Np73 isoforms was shown to inhibit the expression of the glycolysis enzyme
hexokinase 2, through upregulation of peptide hormone amylin. This resulted in the
inhibition of glycolysis, as well as the induction of ROS and apoptosis, consequently
leading to regression of p53-deficient tumors in mice [253]. Accordingly, pramlintide,
a synthetic analogue of amylin, causes rapid tumor regression of p53-deficient thymic
lymphomas in mice [253]. Furthermore, high-throughput metabolic analysis of ∆Np73−/−
mice neurons showed slightly reduced glycolysis and reduced amounts of membrane
phospholipids, long-chain fatty acids, sphingolipids [254], N-acetylaspartylglutamate, and
neurotransmitter glycine, suggesting a delay in neuronal differentiation [251]. Interestingly,
inhibition of polyamine catabolism decreases the ∆Np73/TAp73 ratio in favor of TAp73
and restores sensitivity of the monocytic leukemic cells THP-1 to doxorubicin [255].
In addition to the numerous functions of p73 more or less closely related to tumori-
genesis, during the last decade, many non-oncogenic functions of p73 emerged mainly
due to extensive research on the isoform-specific knockout models [219,256]. p73 plays an
essential role in neuronal development, with the TAp73 isoform playing a more crucial role
in neural development and homeostasis compared to ∆Np73 [256]. TAp73 contributes to
the long-term maintenance of neural stem cells via transcriptional regulation of the bHLH
Hey2, which prevents their differentiation [257]. On the other hand, TAp73 was found
to promote the terminal differentiation of immature neurons through direct induction of
p75NTR and miR34a, which in turn signal via RAS–NF-κB–PI3K and Syt1–Stx1A path-
ways [258,259]. ∆Np73-knockout mice showed only a subtle phenotype in the nervous
system [234,260]. Earlier studies showed that the overexpression of ∆Np73α and ∆Np73β
rescued mature neurons from apoptosis induced by NGF withdrawal or overexpression of
p53 [261]. Furthermore, in vivo, it was found that ∆Np73 plays an essential antiapoptotic
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role during neuronal death in the developing brain [217,261]. Lastly, recently developed
knockout mice with deletion of exon 13 necessary for the α isoforms showed severe hip-
pocampal dysgenesis, reduced synaptic functionality, and impaired learning and memory
capabilities, revealing the indispensable role of the C-terminus in normal development of
the hippocampus [262].
The TAp73 isoforms are recognized as main transcriptional regulators of multicilio-
genesis in airways, oviduct, and brain ependyma. This role explains the airway infections
and infertility observed initially in Trp73−/− mice, as multiciliated cells are crucial for fluid
and germ cell transport across tissue surfaces [263–266]. In male and female reproduction,
TAp73 regulates the gene networks that control cell–cell adhesion programs within the
germinal epithelium to enable germ cell maturation.
Different p73 isoforms participate in various cellular processes, many of which are related
directly or indirectly to tumorigenesis. Some of these functions are shared between several
distinct p73 and p53 isoforms, revealing their potential complementary activities, and some of
them are attributed only to a specific isoform. Thus, p53/p73 isoforms form a complex network
of different functions and activities which are very often based on protein interactions.
9. Crosstalk between p53/p73 Isoforms
Protein interactions are important events in a variety of cellular responses, sometimes
causing the loss of protein activity. This is particularly relevant in the context of cancer cells
expressing the wt p53 protein (or TAp73), whose functionality is needed for an efficient
response to anticancer therapies. Vilgelm et al. showed that p73 and p53 proteins are
co-expressed in colon carcinoma tissues from the same patient [37].
The transactivation function of isoforms of the p53 protein family is executed through the
correct formation of a tetramer through the OD of the monomers (Figure 5A). More precisely,
it is proposed that the p53 dimer binds to a half-site on the consensus DNA sequence and
then is stabilized by binding of the second dimer [267]. In addition, the SAM domain of
p73αmediates protein–protein interactions that are essential for tetramerization and, thus, for
the formation of the active molecule. The transcriptional activity of the individual tetramer
depends on which isoforms it is composed of. Hitherto, we and the others determined
physical interactions between certain isoforms of p53/p73 proteins which are involved in
carcinogenesis and are an important aspect of cancer research [11,28,31,119,268].
The formation of mixed heterocomplexes between oncogenic and antioncogenic
family members correlates with the lack of capacity to transactivate their target genes
(Figure 5B). It is one of two mechanisms for the dominant-negative interference with the
p53 and TAp73 suppressor functions [4]. Certain mt p53 proteins negatively regulate
both wt p53 and TAp73 through a direct physical interaction, which occurs between the
DBD of mt p53 proteins and both the DBD and the OD of TAp73. These interactions were
confirmed under physiological conditions in mammalian cells [195,269,270], causing the
loss of the p53 and TAp73 tumor suppressor functions. Furthermore, mixed protein com-
plexes are formed between endogenous ∆Np73 proteins and either wt p53 or TAp73 in the
human tumor cells and clinical tumor tissue, as well as in primary fibroblasts [31,236,271].
The dominant-negative effect of the ∆Np73 isoforms is performed either through hete-
rocomplex formation with the TAp73 isoforms (Figure 5B) or through competition for
promoter binding with both p53 and TAp73 (Figure 5C) [28,31,268]. The latter mecha-
nism was founded by the notion that p73 and p53 do not form heterotetramers due to
their structurally diverse ODs [272,273]. In both ways, ∆Np73 efficiently interferes with
the p53/TAp73 transactivation function, apoptosis, and growth suppression. When co-
expressed in various cell types, ∆Np73 mediates significant stabilization/accumulation of
TAp73α/β, while simultaneously inhibiting their transactivation ability [274].
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p53/p73 isofor s for ho otetra ers to transactivate target genes; (B) certain p53/p73 isoforms can
form heterotetramers and consequently antagonize p53/TAp73 transactivation ability or (C) compete
with p53/TAp73 for the same promoter sequences, thus exerting a dominant-negative effect; (D) p53β
can modulate the promoter activity of target genes (e.g., BAX) only in the presence of p53α; (E) the p53
isoforms can independently m diate transactivation; (F) the p53 isoforms cooperate with the other
family members, e.g., p73, to medi te transactivation. Adapted from [14,120,277].
There is an autoregulatory feedback loop among p53, TAp73, and ∆Np73. Both p53
and TAp73 induce the expression of the ∆Np73 isoforms via direct binding to the p73-
specific RE within P2 [275]. Induced ∆Np73 in turn negatively regulates the activity of p53
and TAp73 [271,276]. This negative feedback loop is analogous to the p53–MDM2 loop.
We have demonstrated the complex formation between various p53 isoforms (p53β/γ,
∆133p53α/β/γ, ∆40p53α) and TAp73β, while only ∆133p53α/β/γ form a complex with
TAp73α. All p53 isoforms counteract the TAp73β transactivation function but with a differ-
ent efficiency and in a promoter-dependent manner. Interestingly, the TAp73β apoptotic
activity was augmented by p53β [119]. It has also been shown that p53β forms a complex
with p53α and enhances the p53-mediated apoptosis in H1299 cells, although the canonical
OD is partly deleted in p53β isoforms [11]. Later, it was shown that p53β and p53γ coim-
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munoprecipitate with p53α only in the presence of the p53-responsive promoter, indicating
that they modulate p53α transcriptional activity through, at least in part, the formation
of DNA-mediated p53α/p53β and p53α/p53γ protein complexes. Hence, although p53β
and p53γ lack the OD, they can indirectly interact with p53α (Figure 5D) [91].
Furthermore, the ∆40p53α isoform retains the entire OD and directly interacts with
p53α, forming heterotetramers and modifying downstream p53 target genes [14,120]. Con-
sequently, ∆40p53 (also called p47) can act in a dominant-negative manner toward p53α,
inhibiting both the p53-mediated transcriptional activity and the p53-mediated growth
suppression (Figure 5B) [16,195]. However, in melanoma cells, ∆40p53 via heterocom-
plex formation activates and directs p53α to promote apoptosis [172]. Moreover, ∆40p53
reduces the MDM2-mediated degradation of p53 [16,278] and influences the p53 cell lo-
calization [16]. In addition, ∆40p53 can mediate transactivation independently of the
p53α, e.g., ∆40p53 can transactivate BAX and GADD45 in p53-null cells but an oligomeric
complex is still not confirmed (Figure 5E) [120].
∆133p53α interacts with p53α, inhibiting p53α-mediated apoptosis, senescence, and
G1 cell-cycle arrest but not p53-mediated G2 cell-cycle arrest [19,90]. This is another
example of a feedback loop conserved within the p53 gene family, in which p53-induced
∆133p53αmodulates the cellular response to the DNA damage. Obviously, the regulation
of the p53/p63/p73 internal promoters plays an important role in the biological activities
of the p53 family members. However, the dominant-negative effect of ∆133p53 on p53α is
not commonly observed and is probably dependent on cell context.
In addition, the direct interaction between family members has been shown in the
model organisms. Ou and coauthors have shown that protein–protein interaction between
the zebrafish ∆113p53 (a homolog of ∆133p53) and the full-length p53 is essential for the
antiapoptotic function of ∆113p53 [173]. Billant and coworkers studied the dominant-
negative effect within the p53 family in a model of yeast Saccharomyces cerevisiae. All p53
loss-of-function hotspot mutants and transcriptionally inactive isoforms of p53 (∆133p53α
and ∆160p53α) exhibit a dominant-negative potential toward p53α, as well as transcription-
ally inactive ∆Np73α and ∆Np73β. The transcriptionally inactive mutants and isoforms
have an intact OD and are able to form heterotetramers [279].
Noteworthily, the p53 family members interact with each other to regulate common
target genes. In HCT116 colon cancer cells, it was found that p53 and TAp73 isoforms
bind simultaneously to PUMA and p21 promoters. Additionally, the transcription activ-
ity of the entire network of p53 family proteins contributes to the cellular response to
chemotherapeutic drug treatment in colon and esophageal cancer cells [37]. ∆133p53 and
p73 synergistically promote the expression of DNA repair genes in a p53-null environment
of HCT116 colon cancers cells (Figure 5F) [180]. Flores and coworkers demonstrated that,
for the induction of apoptosis, there is an essential teamwork of all family members. Specif-
ically, in the absence of both p63 and p73 (p63/p73−/− double-knockout MEFs), there
is no binding of p53 to the promoters of the proapoptotic BAX, NOXA, and PERP genes.
However, p73, on the other hand, can induce apoptosis in the cells without functional
p53 [280,281].
However, some works support a prion-like p53 aggregation related to the dominant-
negative effect of some hotspot mt p53 [282]. The mutations destabilizing the p53 DBD
generate coaggregation with wt p53, p63, and p73 [283]. Following the finding that p53
associates into amyloid-like aggregates, an ELISA system based on a polyionic, high-
molecular-weight ligand that specifically captures aggregated oligomers and amyloid
proteins was developed. Naturally occurring tetramers of the p53 are not bound, but
high-molecular-weight aggregates are detected in the ovarian cancer cell lines and patient-
derived tumor tissues [284]. Such aggregates could be potential targets for the development
of novel therapeutic strategies against tumors.
To conclude, there is a significant crosstalk between family members in the tumors.
They can bind specifically to the p53RE and modulate the expression of the p53 target
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genes. Through binding to the p53RE, some family members can exert dominant-negative
effects on the activity of p53, p63, and p73.
10. Alterations of the p53 and p73 Isoforms in Cancer
The p53/p73 isoforms have been identified in many different normal and cancer cells
and tissues, including, but not restricted to, ovarian, melanoma, bladder, sarcoma, breast,
kidney, and colon cancer. Their expression has often been found deregulated in tumors
when compared to healthy tissues, which points to their involvement in
tumorigenesis [14,28,145,285]. Here, a few examples are illustrated to accentuate their
frequent occurrence and importance among different tumor types.
Research on ovarian cancer, for example, has shown that the expression of different
p53 isoforms is altered in around 50% of ovarian cancer cell lines and primary ovarian
cancers. More so, expression of p53δ, a splice variant caused by a splice site mutation in
intron 9, was associated with impaired response to platinum-based chemotherapy and
has been identified as a prognostic marker for the recurrence-free and overall survival of
ovarian carcinoma patients. p53β was also correlated with adverse clinical features and
worse recurrence-free survival in patients exhibiting functionally active p53. Among p73
isoforms, ∆N′p73 was the preferentially expressed ∆N isoform in ovarian cancer cells with
functionally active p53 [286]. ∆N′p73 was also found to be overexpressed in ovarian cancer
in another study where about one-third of samples exhibited upregulation of TAp73 and to
a lesser extent ∆Np73. The correlation analysis pointed toward better overall survival in
patients with low expression of ∆N′p73/∆Np73 [287]. Zaika and colleagues showed that
the ∆Np73 is overexpressed in a panel of different tumors but not in normal tissue [28].
Studies on renal cell cancer (RCC) showed that, in wt p53 tumors, the expression of ∆133p53
was downregulated compared to normal adjacent tissue [288]. Unlike in other tumors, p53
is rarely mutated in melanoma, but still fails to protect melanocytes from tumorigenesis.
It was hypothesized that the p53 family isoforms might have a role in this phenomenon.
Ozretić and colleagues tested this hypothesis by investigating the expression profile of
p53/p73 family isoforms in melanoma cell lines and metastatic melanoma samples. The
tumor samples showed lower expression of ∆40p53β and ∆Np73 mRNA and ∆Np73β
protein, as well as elevated protein levels of ∆133p53α, ∆160p53α and ∆Np73α. Moreover,
the higher expression of ∆133p53β and p53α mRNA and the lower expression of p53β
mRNA were connected to shorter overall survival [9].
11. Alterations of the p53/p73 Isoforms Expression in Colorectal Cancer
The p53 family is expressed as an intricate network of isoforms in both normal and
tumor colorectal tissue. Recently conducted genome-wide alternative splicing analysis on
the CRC cohort from TCGA database emphasized the importance of alternative splicing
events in the p53 signaling pathway in CRC metastasis and recurrence [289]. Several papers
have been published supporting this conclusion.
A high expression of the canonical p53, ∆133p53α and β, a moderate expression of
∆133p53γ, and a lower expression of p53β and γ have been reported in normal colon
tissue [11]. Colon adenoma tissues express elevated levels of p53β and reduced levels
of ∆133p53 isoforms compared to non-adenoma and normal colon tissue. However, the
expression of ∆133p53 increases from stage I to II, whereas that of p53β decreases from
stage II to III in the colon carcinoma, displaying an interesting dynamic during cancer
progression [19]. In agreement with this, the high upregulation of ∆133p53 transcript level
in colon cancers was also found in another study [184].
In normal colon, a low gene and protein expression of both TAp73 and ∆Np73 was
found compared to the colorectal adenocarcinomas. Interestingly, the prevalence of p73α
and β gene expression was shown by nested PCR, compared to p73γ, δ, φ, and ε in both
normal and tumor tissue [37]. Another study reported primarily the mRNA expression
of ∆Np73 in normal and premalignant tissue. However, in CRC, the expression of both
isoforms was elevated [290]. Accordingly, strong cytoplasmic ∆Np73 protein staining was
Cancers 2021, 13, 2885 24 of 42
detected in normal rectal tissue [291]. Colon cancer tissue showed increased co-expression
of TAp73 and ∆Np73 compared with normal epithelial colon tissue [37,290,292], indicating
the involvement of both isoforms in colon carcinogenesis. Of note, ∆Np73 and ∆Ex2/3p73
expression increased with cancer stage [137,293,294]. ∆Np73 protein staining was increased
in rectal cancer tissue compared to normal rectal tissue [291], as well as in γ-irradiation-
resistant colon cancer cell line KM12C [295].
∆Np73βmRNA has also been identified as an exosomal cargo from ∆Np73β ectopi-
cally expressing HCT116 colon cancer cells, and it is selectively packed into exosomes from
CRC patients when compared to exosomes from healthy controls. The transmission of
exosome cargo to epithelial, fibroblast, and endothelial cells and its significant effect on
proliferation and drug resistance in the acceptor cells were observed. This finding supports
the potential prognostic value of the exosomal ∆Np73 in colon cancer patients [292].
These data paint a complex image of the p53/p73 isoform network in colon healthy
tissues, as well as colorectal tumors.
12. Involvement of the p53/p73 Isoforms in CRC Development and Progression
Since the p53 family proteins are involved in a plethora of cell signaling pathways that
regulate processes such as survival, proliferation, differentiation, apoptosis, and motility of
both healthy and cancer cells [4,296–298], it is of no surprise that particular isoforms are
implicated in CRC as well (Table 1). However, to our knowledge, roles of the p53 isoforms
have still not been investigated thoroughly in CRC (Figure 6).
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Among the few papers tackling the role of p53 isoforms in colorectal cancer, Katoch
and colleagues sho ed that ∆40p53 downregulates the expression of the transcriptional
repressor protein YY1 via upregulating miR-186 which consequently inhibits cell pro-
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liferation of HCT116−/− cells [187]. There is also evidence of ∆40p53’s involvement in
autophagy in the ∆40p53 ectopically expressing HCT116 cells. More specifically, it was
shown that ∆40p53 has 3′–5′ exonuclease capacity, which contributes to its role in inhibit-
ing autophagy [186]. Arsic and colleagues showed that the ∆133p53β isoform specifically
binds to a tumor suppressor RhoB (Ras homolog family member B) and negatively reg-
ulates its GTPase activity, which in turn protects CRC cells from camptothecin-induced
apoptosis [175]. ∆133p53 in complex with TAp73α has been implicated in DNA DSB repair
upon γ-irradiation in HCT116 cells. In more detail, experiments showed that these two
isoforms accumulate 24 h post irradiation and synergistically cooperate to promote the
expression of RAD51, LIG4, and RAD52 by binding to their promotors. Furthermore, the
knockdown of TAp73 causes accumulation of DNA DSBs, which leads to G2 cell-cycle
arrest and promotes cell senescence upon γ-irradiation. Interestingly, mutations in the
∆133p53 promoter region reduce its activation in response to DNA damage, which may
be related to tumorigenesis [180]. Diaz and colleagues directly associated the TAp73 and
∆Np73 isoforms with antiapoptotic protein survivin in colon cancer cells. Specifically,
experiments on SW480-ADH and HCT116 cell lines showed that 1α,25-dihydroxyvitamin
D3 treatment significantly downregulated survivin, which led to a decrease in TAp73 and
∆Np73. On the other hand, the ectopic expression of survivin caused an increase in TAp73
and ∆Np73, as well as ∆Ex2p73 and ∆Ex2/3p73, transcripts. Furthermore, direct correla-
tions between ∆Np73, ∆Ex2p73, or TAp73 isoforms and survivin levels were observed in
colon cancer tumor samples, pointing to their antiapoptotic role [299]. On the other hand,
Dabiri and colleagues implicated the TAp73 isoform as a proapoptotic actor in CRC cells
lacking functional p53. Using p53-null HCT116 cells, the authors showed that the transient
resistance to inhibitor bortezomib is abolished by the nuclear translocation of TAp73, which
causes apoptosis. Similar results were observed in mt p53 HT-29 cells, but not in human
fibroblasts expressing wt p53, indicating that TAp73 could be a potential therapeutic target
for the treatment of CRC lacking functional p53 [300]. The ectopic expression of ∆Np73 iso-
forms in HCT116 cells was associated with an increase in proliferation and drug resistance
to oxaliplatin [293].
Further experiments confirming the oncogenic role of the ∆Np73 isoforms in CRC
showed that ∆Np73 overexpression increased the colonosphere formation of CRC cells
DLD1 and significantly reduced cell death in HCT116 and DLD1 caused by a small-
molecule prodigiosin, which restores the p53 pathway [301]. Interestingly, when ∆Np73α
was overexpressed in wt p53 HCT116, it did neither affected cellular/tumor growth nor the
response to anticancer treatment with cisplatin or doxorubicin in vitro and in vivo [302,303].
Similar results were obtained in another study on p53-null HCT116 and H1299 cell lines
with stable overexpression of ∆Np73α [304]. Lööf and colleagues showed that the over-
expression of ∆Np73β increased cellular viability but did not affect cellular susceptibility
to cisplatin in both wt p53 and mt p53 HCT116. Interestingly, cisplatin decreased the ex-
pression levels of ∆Np73β in a dose-dependent manner [305]. Furthermore, the exosomal
∆Np73β mRNA from HCT116 cells ectopically expressing ∆Np73β increased prolifera-
tion and oxaliplatin chemoresistance in vitro in recipient cells. Moreover, the HCT116
xenografts in mice injected with exosomes from the ∆Np73β-overexpressing cells were
significantly bigger compared to controls, showing a higher percentage of proliferative
marker Ki67-positive cells and a higher level of the ∆Np73β expression [292].
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Table 1. Involvement of the p53/p73 isoforms in colorectal cancer development and progression. The p53/p73 family of
isoforms is associated with a plethora of cancer-related cellular functions such as apoptosis and sensitivity to drugs, DNA
repair, autophagy, proliferation, inflammation, invasion, angiogenesis, metabolism, and senescence.
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Table 1. Cont.
Cellular Function Isoform Model Signalling Effect Reference
Metabolism
p53 and ∆40p53 HCT116 and A549
Glucose starvation→
↑SMAR1 ↑ IRES ↑
TIGAR
- [109]
TAp73 HCT116 and HCT116p53−/− ↑ G6PD ↑ proliferation [307,308]
TAp63 Patient-derivedCCSCs - ↑ glycolytic activity [309]
Senescence
↑ p53β and ↓
∆133p53 CRA patient samples - ↑ senescence
[19]
↓ p53β and ↑
∆133p53 CRC patient samples
Escape from senescence
barrier
↓, decreased activity, expression, or effect; ↑, increased activity, expression, or effect; →, leads to; =, unchanged; Casp3, caspase 3;
CCSCs, colon cancer stem cells; cDDP, cis-diammine-dichloro-platinum; CRA, colorectal adenoma; CRC, colorectal carcinoma; DRAM,
damage-regulated autophagy modulator 1; DX, doxorubicin; Eif2, eukaryotic initiation factor 2; G6PD, glucose-6-phosphate dehydrogenase;
LIG4, DNA ligase 4; IL-6, interleukin 6; IL-8, interleukin 8; IRES, internal ribosome entry site; PEDF, pigment epithelium-derived factor;
PKR, protein kinase R; RhoB, Ras homolog family member B; TIGAR, TP53-induced glycolysis regulatory phosphatase; VEGF, vascular
endothelial growth factor.
Experiments have revealed that the p53 isoforms, particularly ∆133p53, are involved
in the invasion of CRC. Campbell and colleagues showed that all three ∆133p53 isoforms
(α, β, and γ) promote invasion of HCT116 through matrigel via RhoA and ROCKA (Rho-
associated protein kinase A). Furthermore, cells transfected with ∆133p53α display a
more rounded phenotype [188]. Similarly, ∆133p53 is expressed in higher amounts in
the invasive CRC cell lines independently of the p53 mutational status. Additionally,
HCT116 cells depleted of all p53 isoforms other than ∆133p53 become more invasive, while
those transfected with siRNA specific for p53β isoforms become less invasive in vitro,
suggesting that the p53 isoform ratio, including ∆133p53β, defines the invasive activity
of the cells. Interestingly, the ectopic expression of ∆133p53β in HCT116 cells initiated
epithelial–amoeboid transition, a derivative of epithelial-mesenchymal transition, which
produces highly invasive cells [192].
The p73 isoforms may have a role in modifying the expression levels of the angiogenesis-
related factors in CRC, which is yet to be understood. Díaz and coauthors found correlations
between the expression levels of the proangiogenic VEGF-A (vascular endothelial growth
factor A) and ∆Np73 and TAp73 in a cohort of CRC patient samples. Interestingly, the
expression of ∆Ex2p73, ∆Ex2/3p73, ∆Np73, or TAp73 correlated with the expression of a
putative antiangiogenic isoform VEGF165b. However, the expression of ∆Ex2p73 inversely
correlated with the antiangiogenic protein PEDF (pigment epithelium-derived factor) [306].
p53 isoforms have been implicated in the cellular metabolism of CRC. For example,
glucose starvation promotes IRES in lung and colon cancer cells that is regulated via the
SMAR1 (scaffold/matrix attachment region-binding protein 1) protein and elevates the
expression of TIGAR (TP53-induced glycolysis regulatory phosphatase) whose product
is involved in glycolysis [109]. In addition, higher glycolytic activity was observed in
the colon CSCs expressing TAp63 compared to the colon CSCs expressing ∆Np63, which
implies that the p63 isoforms regulate their glucose metabolism [309]. Furthermore, TAp73
activates the expression of the pentose phosphate pathway enzyme glucose-6-phosphate
dehydrogenase (G6PD), which supports tumor cell proliferation in both p53 wt and −/−
HCT116 [307,308].
Furthermore, the ectopic expression of ∆133p53 in HCT116 cells increases the expres-
sion of the NF-κB targets interleukin 6, 8 and antiapoptotic protein Bcl-2, probably through
inhibition of p53 [93].
p53β and ∆133p53 show dynamic correlation in the development of colon carcinoma.
Increased levels of p53β and reduced levels of ∆133p53 in colon adenoma tissues have
been described as a senescence-associated p53 isoform signature that may represent a
senescence barrier observed in premalignant tumors. Interestingly, in CRC tissues, this
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signature is lost and even reversed with cancer stage, which may indicate an escape from
the senescence barrier during the progression from adenoma to carcinoma [19].
13. Prognostic Relevance of the p53/p73 Isoforms Expression in CRC
The mutation status of an established tumor suppressor protein such as p53 has sur-
prisingly limited relevance in cancer progression diagnostics. One reason might be the
overly simplified image of its action, neglecting the existence of the p53 family isoforms
which act in concert. Therefore, the question is whether the p53 family isoforms could
have a better diagnostic ability for cancer patients than the canonical protein itself. In that
context, Campbell and colleagues showed that the CRCs with elevated ∆133p53 mRNA are
more aggressive and are associated with a shorter disease-free survival (DFS) [188]. More-
over, high expression of the ∆133p53βmRNA is correlated with higher risk of metastatic
recurrence in patients with locally advanced rectal cancer [175]. There is still a large area to
explore in the context of potential prognostic value of the remaining p53 isoforms in CRC.
On the other hand, more extensive research on the prognostic relevance of the p73 isoforms
has already been undertaken. The overexpression of the p73 variants is mostly associated
with adverse colon tumor features. More specifically, an association was found between
the expression of ∆Np73 or ∆Ex2/3p73 and the CRC tumor stage, as well as between
the upregulation of ∆Ex2p73, ∆Ex2/3p73, or TAp73 and the presence of polyps [137,294].
The ∆Np73 overexpression was also associated with vascular invasion of CRC and high
levels of the ∆Ex2/3p73 variant with lymph node metastases [294]. Colon cancer patients
showed reduced DFS associated with ∆Np73 [310], and the overexpression of ∆Np73
and ∆Ex2/3p73 isoforms was associated with advanced stages, as well as shorter OS
and DFS [292,293]. ∆Np73 expression was also related to the local recurrence of rectal
cancer [291]. However, the same authors revealed a correlation of ∆Np73 expression and
long survival time of rectal cancer patients who were subjected to preoperative radiother-
apy [311]. Interestingly, higher levels of ∆Np73 in patient-derived exosomes were also
noted in sera of advanced-stage CRC patients and were associated with shorter DFS [292].
In conclusion, most papers correlate malignant characteristics of colon cancer with the
elevated expression of ∆Np73 isoforms.
Findings have shown that p53 autoantibodies are produced early during tumor de-
velopment in CRC patients, making the p53 autoantibodies promising markers for early
detection [312,313]. Research on seropositivity extended from the canonical p53 protein
to p53 family isoforms has been done in CRC patients. More specifically, sera were tested
for total p73, ∆Np73α, and ∆Np73β autoantibodies, and results revealed higher ∆Np73α
and ∆Np73β seroreactivity of CRC samples when compared to healthy individuals. Impor-
tantly, autoantibodies to both isoforms showed diagnostic ability separately and even better
in combination in discriminating between CRC and healthy individuals. Interestingly, the
∆Np73 isoform autoantibodies showed even higher diagnostic ability than the canonical
protein TAp73α [290].
These data point to the importance of investigating isoforms hand in hand with the
canonical proteins themselves in cancer research.
14. Targeting the p53/p73 Family Isoforms in CRC
Since there is ongoing evidence that p53 family isoforms act as epigenetic p53 in-
hibitors in cancer, the potential of targeting them in colon cancer has been investigated,
with the goal of reactivating the p53 pathway and getting a better response to therapy.
Zhang and colleagues published an interesting article where they, after a functional cell-
based assay screening of almost 2000 small molecules, identified NSC59984 as that which
specifically restores the p53 pathway in mt p53 CRA cells SW480 and DLD-1 via activation
of TAp73. Importantly, a favorable therapeutic index between normal and cancer cells was
presented. The authors showed that NSC59984 not only induces TAp73-dependent cell
death in cancer cells in vitro but also synergizes with the DNA-damaging agent CPT11
in inducing cell death of mt p53-expressing cells [314]. Furthermore, β-cryptoxanthin, a
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carotenoid contained primarily in citrus fruits, has shown an effect on p53 family signaling.
More precisely, β-cryptoxanthin treatment in vitro upregulated TAp73 and downregu-
lated ∆Np73, ∆Ex2/3p73, and ∆Ex2p73 mRNA levels in most of the colon cancer cells
investigated. An intervention study in humans showed that intake of β-cryptoxanthin-
enriched juice also affected the expression of p73 isoforms in leukocytes, where significant
downregulation of ∆Np73 has been found. Furthermore, β-cryptoxanthin decreased the
proliferation of colon cancer cells and HCT116 xenografts and enhanced the effect of oxali-
platin in inducing apoptosis and a reduction in tumor volume [315]. Nutlin-3, an already
well-known small-molecule inhibitor, which activates p53 by disrupting the p53–MDM2
association, has also been tested in the p53-null CRC background. When p53 is absent from
HCT116 cells, nutlin-3 inhibits MDM2 binding to TAp73α, which leads to the upregulation
of TAp73 protein levels, prolongation of the p73 half-life, and an increase in its transcrip-
tional activity. Consequently, the transcription of p73 target genes NOXA, PUMA, and p21
leads to an increase in apoptosis [316]. Interesting research has also been done on colorectal
cancer stem cells (CRCSC), a rare self-renewing cell subpopulation which adds a further
layer of complexity to cancer treatment because they contribute to tumor maintenance and
chemoresistance. Prabhu and colleagues showed that a small-molecule prodigiosin, which
restores the p53 pathway in cancer cells, is also effective on 5-FU chemoresistant CRCSCs
in vitro and in vivo. More specifically, prodigiosin increases the level of TAp73 and de-
creases ∆Np73 in a c-Jun-dependent manner. This research highlighted the involvement of
the p73 pathway in the maintenance of stem potential of CRCSC, as well as the potential of
p53 pathway-activating therapeutics to target colorectal cancer [301].
Since p53 isoforms are differentially expressed in CRA and CRC and correlated
to patient prognosis, their targeting to restore the p53 signaling pathway alone or in
combination with already established anticancer agents presents an attractive strategy for
CRC therapy.
15. Conclusions
The p53 family members play a significant role in carcinogenesis and treatment
response. In addition to the fact that p53 is often mutated in tumors, it has become
evident that different expression patterns of its isoforms are relevant in carcinogenesis.
Furthermore, in tumors with mutated or otherwise inactivated p53, substituting its tumor
suppressor function by TAp73 is a possible therapeutic approach. However, the existence
of p53-like and p53-inhibitory isoforms, as well as a close functional crosstalk among all
family members, gives the p53 family isoforms both tumor suppressor and oncogenic
roles. To completely understand and decipher the role of the p53 and p73 isoforms in
cancer, it is important to explore the mechanism supporting the dysregulation of isoform
balance, as well as perform clinicopathologic studies which correlate the co-expression
of p53 family isoforms with p53 mutation status and clinical outcome. Once the complex
regulation of the p53 family isoforms is fully understood, they can be used as biomarkers
or as therapeutic options.
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